GRTS News and Press, Gritstone Oncology Inc. From 04/01/24

2024-04-01 16:55:25 ET More on Gritstone bio, Humana, etc. UnitedHealth Group: Buy The Recent Pullback - Long-Term Tailwinds Remain Excellent UnitedHealth Group: Optum To Drive Growth But Watch For Regulatory Risk Humana: This Year's Drop Might Have Created A Buying ...

2024-04-01 16:15:17 ET More on Gritstone bio Gritstone bio: Looking For Validation In 2024 Gritstone to cut 40% of staff due to funding delay, stock plunges 23% Seeking Alpha’s Quant Rating on Gritstone bio Historical earnings data for Gritstone bio ...

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that it has commenced an underwritten public offering of shares of its common stock (o...

-- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction of progression or death with GRANITE vs. control) in a high-risk group, where clinical data are m...

2024-03-28 15:00:00 ET More on the markets Where This Market Is Going (Technical Analysis) SPY: 2 Opposing Forces Wall Street Lunch: Fed Not Spooked By Recent Inflation Overbought conditions flash across all market caps: Bespoke Investment Group Energ...

2024-03-05 16:32:03 ET More on Gritstone bio Gritstone bio: Looking For Validation In 2024 Gritstone to cut 40% of staff due to funding delay, stock plunges 23% Seeking Alpha’s Quant Rating on Gritstone bio Historical earnings data for Gritstone bio ...

-- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating GRANITE, Gritstone’s personalized cancer vaccine in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC) remain expected in 1Q 2024 -- -- National Cancer Institute-led Phase 1 study evaluat...

EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced an approximately 40% reduction of its workforce. The move comes following the recently annou...

EMERYVILLE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor and scientific conferences: ...

2024-02-16 16:37:46 ET Gainers: Iovance Biotherapeutics ( IOVA ) +4% . Microvision ( MVIS ) +3% . Iridium Communications  ( IRDM ) +3% . Playtika Holding  ( PLTK ) +2% . JetBlue Airways  ( JBLU ) +2% . Losers...